PrimoNeryLaraJr.MD

Genitourinary Oncology, Thoracic Cancer

Director, UC Davis Comprehensive Cancer Center Codman-Radke Endowed Chair for Cancer Research Executive Associate Dean for Cancer Programs and Professor of Medicine, UC Davis School of Medicine

Join to view full profile

Dr. Lara is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lara's full profile

Already have an account?

Office
4501 X St
Sacramento, CA 95817
Phone+1 916-734-3772

Fax+1 916-734-7946
Is this information wrong?

Education & Training

University of California Davis HealthFellowship, Hematology and Medical Oncology, 1996 - 1999
Rush University Medical CenterResidency, Internal Medicine, 1993 - 1996
University of the Philippines College of MedicineClass of 1992

Certifications & Licensure

CA State Medical License 1995 - 2025
IL State Medical License 1993 - 1996
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy Start of enrollment: 2000 Aug 01
Completed
Phase 2
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer Start of enrollment: 2000 Nov 01
Completed
Phase 2
Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 2
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2001 Jun 01
Completed
Phase 2
R115777 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2001 Aug 01
Completed
Phase 1
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 3
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2002 May 01
Completed
Phase 2
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Nov 01
Completed
Phase 3
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium Start of enrollment: 2003 Jan 01
Completed
Phase 2
Perifosine in Treating Patients With Recurrent Prostate Cancer Start of enrollment: 2003 Mar 01
Terminated
Phase 2
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer Start of enrollment: 2003 Sep 01
Completed
Phase 2
Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Start of enrollment: 2003 Sep 01
Completed
Phase 2
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2004 Jan 01
Completed
Phase 2
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2006 Aug 01
Completed
Phase 3
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Jul 01
Completed
Phase 2
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer Start of enrollment: 2004 Sep 01
Terminated
Phase 2
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 2
Sorafenib in Treating Patients With Advanced Malignant Solid Tumors Start of enrollment: 2008 Dec 01
Completed
Phase 2
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 2
Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy Start of enrollment: 2009 May 01
Completed
Phase 2
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis Start of enrollment: 2009 Sep 01
Terminated
Not Applicable
Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors Start of enrollment: 2010 Feb 01
Completed
Phase 1
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer Start of enrollment: 2010 Dec 01
Completed
Phase 2
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Start of enrollment: 2011 Feb 01
Completed
Phase 2
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Start of enrollment: 2011 Sep 06
Completed
Phase 1
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Start of enrollment: 2014 Jan 22
Active, not recruiting
Phase 3
Radiologically Guided Biopsies of mCRPC Start of enrollment: 2013 Feb 22
Completed
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Start of enrollment: 2015 Sep 01
Completed
Phase 1
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Start of enrollment: 2015 Aug 17
Active, not recruiting
Phase 2
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer Start of enrollment: 2016 Nov 15
Completed
Phase 1, Phase 2
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Start of enrollment: 2017 Aug 24
Active, not recruiting
Phase 2
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2017 Jul 19
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S...
Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo, Andrea Harzstark, Channing J Paller, Saby George, Matthew R Zibelman, Heather ...> ;European Urology Oncology. 2024 Mar 23
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Hilary Bagshaw, Michael Baine, Kathryn Beckermann, Maria I Carlo, Toni K Choueiri, Brian A Costello, Ithaar ...> ;Journal of the National Comprehensive Cancer Network. 2024 Feb 1
Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023.
Gulati, S., Lara, P.> ;Kidney Cancer. 2024 Jan 1
Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer.
Yixin Chen, Mei-Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N Lara, Hong-Wu Chen, Huichang Bi, Ai-Ming Yu> ;Acta Pharmaceutica Sinica. B. 2023 Oct 1
4 citations
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
Arian Lundberg, Meng Zhang, Rahul Aggarwal, Haolong Li, Li Zhang, Adam Foye, Martin Sjöström, Jonathan Chou, Kevin Chang, Thaidy Moreno-Rodriguez, Raunak Shrestha, Avi...> ;Cancer Research. 2023 Aug 15
6 citations
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
Sadeghi, S., Quinn, D., Dorff, T., Pal, S., Groshen, S., Tsao-Wei, D., Parikh, R., Devitt, M., Parikh, M., Jackovich, A., Ruel, N., Vogelzang, N., Burgess, E., Siddiqi...> ;Journal of Clinical Oncology. 2023 Jan 20
2 citations
A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer.
Xing Yi Woo, Anuj Srivastava, Philip C Mack, Joel H Graber, Brian J Sanderson, Michael W Lloyd, Mandy Chen, Sergii Domanskyi, Regina Gandour-Edwards, Rebekah A Tsai, J...> ;Cancer Research. 2022 Nov 15
3 citations
ATR Inhibition in Advanced Urothelial Carcinoma.
Ryan C Leibrandt, Mei-Juan Tu, Ai-Ming Yu, Primo N Lara, Mamta Parikh> ;Clinical Genitourinary Cancer. 2023 Apr 1
13 citations
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
Martin Sjöström, Shuang G Zhao, Samuel Levy, Meng Zhang, Yuhong Ning, Raunak Shrestha, Arian Lundberg, Cameron Herberts, Adam Foye, Rahul Aggarwal, Junjie T Hua, Haolo...> ;Cancer Research. 2022 Nov 2
15 citations
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
Neeraj Agarwal, Catherine M Tangen, Maha H A Hussain, Shilpa Gupta, Melissa Plets, Primo N Lara, Andrea L Harzstark, Przemyslaw W Twardowski, Channing J Paller, Dylan ...> ;Journal of Clinical Oncology. 2022 Oct 1
10 citations
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
Thomas C Westbrook, Xiangnan Guan, Eva Rodansky, Diana Flores, Chia Jen Liu, Aaron M Udager, Radhika A Patel, Michael C Haffner, Ya-Mei Hu, Duanchen Sun, Tomasz M Beer...> ;Nature Communications. 2022 Sep 15
9 citations
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
Daniel M Girardi, Scot A Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K Pal, Biren Saraiya, Lisa Cordes, Lisa Ley, Olena Sierra Ortiz, Jacqueline Cadena, Ca...> ;Clinical Cancer Research. 2022 Apr 1
1 citations
Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor.
Shuchi Gulati, Primo Nery Lara> ;Kidney Cancer. 2022 Jan 1
1 citations
Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer.
Mamta Parikh, Primo N Lara> ;Kidney Cancer. 2022 Jan 1
225 citations
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I Carlo, Toni K Choueiri, Brian A Costello, Ithaar H Derweesh, Arpi...> ;Journal of the National Comprehensive Cancer Network. 2022 Jan 1
20 citations
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Sumanta K. Pal, Paul Frankel, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou, Peng Weng, Rahul R. Parikh, Benjamin A. Teply, Robert...> ;JAMA Oncology. 2021 Oct 1
5 citations
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)
Toni K. Choueiri, Yousef Zakharia, Sumanta K. Pal, Judit Kocsis, Russell K. Pachynski, Alexandr Poprach, Andrew B. Nixon, Yingmiao Liu, Mark D. Starr, Jing Lyu, Kouros...> ;The Oncologist. 2021 Jul 1
8 citations
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
Jonathan W. Riess, Karen L. Reckamp, Paul Frankel, Jeffrey Longmate, Karen Kelly, David R. Gandara, Caroline M. Weipert, Victoria M. Raymond, Harold N. Keer, Philip C....> ;Clinical Lung Cancer. 2021 May 15
2 citations
Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group.
Diego Abreu, Gustavo F. Carvalhal, Guillermo Gueglio, Ignacio Tobia, P. García, Álvaro Zúñiga, Luis Meza, Rubén G. Bengió, C. Scorticati, Ricardo Castillejos, Francisc...> ;JCO Global Oncology. 2021 May 1
37 citations
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer.
Mamta Parikh, Chengfei Liu, Chun Yi Wu, Christopher P. Evans, Marc A. Dall'Era, Daniel Robles, Primo N. Lara, Neeraj Agarwal, Allen C. Gao, Chong-Xian Pan> ;Scientific Reports. 2021 Mar 18
13 citations
In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy.
Peng Cheng Li, Mei Juan Tu, Pui Yan Ho, Neelu Batra, Michelle M.L. Tran, Jing Xin Qiu, Theodore Wun, Primo N. Lara, Xiang Hu, Ai Xi Yu, Aiming Yu> ;Theranostics. 2021 Mar 4
18 citations
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
Heather J. Chalfin, Tiziano Pramparo, Amir Mortazavi, Scot Anthony Niglio, Joseph D. Schonhoft, Adam Jendrisak, Yen Lin Chu, Robin Richardson, Rachel Krupa, Amanda K. ...> ;Clinical Cancer Research. 2021 Mar 1
120 citations
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Sumanta K. Pal, Catherine M. Tangen, Ian M. Thompson, Naomi S. Balzer-Haas, Daniel J. George, Daniel Y.C. Heng, Brian Shuch, Mark N. Stein, Maria S. Tretiakova, Peter ...> ;Lancet. 2021 Feb 20
15 citations
Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate-sensitive prostate cancer (SWOG S1216)
Amir Goldkorn, Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu, Jacek Pinski, Sue A. Ingles, Timothy J. Triche, Andrea L. Harzstark, Mani...> ;Clinical Cancer Research. 2021 Jan 26
13 citations
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.
Caroline E. McCoach, Aiming Yu, David R. Gandara, Jonathan W. Riess, Daniel P. Vang, Tiahong Li, Primo N. Lara, Matthew A. Gubens, Frances Lara, Philip C. Mack, Laurel...> ;JCO Precision Oncology. 2021 Jan 14
Join now to see all

Journal Articles

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung Carcinoma
Beth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer

Lectures

Pilot trial of ibrutinib plus nivolumab in patients with metastatic renal cell cancer (mRCC): results from a dose-finding cohort.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Great Debates and Updates In Thoracic Malignancies
Imedex, San Francisco, California - 5/5/2012

Authored Content

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018

Press Mentions

Coping with the Side Effects of Kidney-Cancer TreatmentOctober 27th, 2022
UC Davis Cancer Center Charges Forward in the New Era of 'Transformative' Cancer TreatmentsJuly 1st, 2022
Researchers Develop New Standard of Care to Treat Rare Papillary Kidney CancerMarch 12th, 2021
Join now to see all